Skip to main content
Fig. 2 | AAPS Open

Fig. 2

From: Utilizing cross-product prior knowledge to rapidly de-risk chemical liabilities in therapeutic antibody candidates

Fig. 2

Cross-product analysis of CDR potential liabilities. A Cross-product motif prevalence showing the percentage of commercial mAbs that have the same motif at the same position as the query (mAb1) in the aligned sequence. Residue numbers correspond to the linear position in mAb1. B Box plots of experimental data spanning discovery to late phase from prior molecules under various stress conditions with the same motif at the same position in the aligned sequence as the query (mAb1) provide additional insight into the likelihood and potential magnitude of modifications in the query sequence

Back to article page